Bain, Atlas, RTW back new biotech developing obesity drugs with $400M
A new obesity biotech has entered the field — and it has $400 million from well-known life sciences investors to test investigational GLP-1 and GIP candidates licensed from Jiangsu Hengrui Pharmaceuticals.
Bain Capital Life Sciences, Atlas Venture, RTW and Lyra Capital have invested in a new biotech named Hercules CM NewCo, per an
announcement
this week from China-based Hengrui.
Hercules’ pipeline now includes the global, ex-China rights to HRS-7535, HRS9531 and HRS-4729, according to the release. The deal includes $110 million in upfront payments to Hengrui, according to a source familiar with the deal. Hercules, a placeholder name for the biotech, will be based in the US, the source said. The new company is a partnership between Bain, Atlas and RTW, the source added.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.